Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment

Launched by RUIJIN HOSPITAL · Aug 31, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on understanding hospital-acquired pneumonia (HAP), a type of lung infection that people can develop while being treated in a hospital. Researchers in China want to learn more about the germs that cause this infection, how they behave, and how resistant they are to antibiotics (medications used to treat infections). The study aims to identify differences in these germs across different regions of China and over time, as well as to create a network for tracking this information.

To participate in the trial, individuals must be 18 years or older and diagnosed with hospital-acquired pneumonia based on specific criteria, including symptoms like fever and abnormal chest X-ray results. Participants should also have evidence of the bacteria causing their infection. It's important to note that those with certain conditions, such as active tuberculosis or severe immune system issues, will not be eligible. If you join this study, you can expect to contribute to important research that may help improve the diagnosis and treatment of hospital-acquired pneumonia in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years old.
• • 2. Meets the clinical diagnostic criteria for HAP in the 2018 HAP/VAP guidelines. Chest X-ray or CT shows new or progressive infiltrative shadows, consolidation shadows, or ground glass shadows, combined with 2 or more of the following 3 clinical symptoms, to establish a clinical diagnosis: 1) Fever, body temperature\>38 ℃; 2) Purulent airway secretions; 3) Peripheral blood white blood cell count \>10 × 10\^9/L or \<4 × 10\^9/L.
• • 3. Having qualified evidence of responsible pathogen. On the basis of clinical diagnosis, one of the following conditions should be met simultaneously: 1) Qualified lower respiratory tract secretions (neutrophil count \>25/low magnification field, epithelial cell count \<10/low magnification field, or a ratio of the two \>2.5:1), pathogenic bacteria cultured through bronchoscopy anti pollution brush (PSB), bronchoalveolar lavage fluid (BALF), lung tissue or sterile body fluid, and consistent with clinical manifestations; 2) Pathology, cytopathology, or direct microscopic examination of lung tissue specimens showing fungi and evidence of tissue damage; 3) The serum IgM antibodies of atypical pathogens or viruses change from negative to positive, or the titers of specific IgG antibodies in both acute and recovery phases show a 4-fold or more change. During the outbreak of respiratory viruses and with a history of epidemiological contact, respiratory secretions were tested positive for corresponding virus antigens, nucleic acid tests, or virus culture.
• • 4. obtained informed consent
• Exclusion Criteria:
• • 1. Those who cannot understand and execute the investigation plan.
• • 2. Active pulmonary tuberculosis;
• • 3. Severely immunosuppressed patients: absolute neutrophil count \<0.5× 10\^9/L, CD4\<200/ml.